Rival cholesterol drugs Praluent and Repatha have struggled as insurance companies and benefit managers have made it difficult for patients to get the treatment. Because they were so expensive, even for patients with a genetic disorder that causes super-high cholesterol, insurers rejected the drugs 63 percent of the time. Now, both of their list prices have been cut, a move that could possibly hint at a change in the drug pricing system on the horizon. In other pharmaceutical news, brain cancer drugs, fatty liver disease and vaccines.
This post was originally published on this site